- Home
- PRCT vs KNSA Comparison
PRCT vs KNSA Comparison
Compare PRCT & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRCT
- KNSA
- Stock Information
- Founded
- PRCT 2009
- KNSA 2015
- Country
- PRCT United States
- KNSA United Kingdom
- Employees
- PRCT N/A
- KNSA N/A
- Industry
- PRCT Medical Specialities
- KNSA Biotechnology: Pharmaceutical Preparations
- Sector
- PRCT Health Care
- KNSA Health Care
- Exchange
- PRCT Nasdaq
- KNSA Nasdaq
- Market Cap
- PRCT 2.2B
- KNSA 1.9B
- IPO Year
- PRCT 2021
- KNSA 2018
- Fundamental
- Price
- PRCT $41.59
- KNSA $33.38
- Analyst Decision
- PRCT Buy
- KNSA Strong Buy
- Analyst Count
- PRCT 8
- KNSA 6
- Target Price
- PRCT $75.57
- KNSA $40.83
- AVG Volume (30 Days)
- PRCT 1.6M
- KNSA 707.4K
- Earning Date
- PRCT 08-06-2025
- KNSA 07-29-2025
- Dividend Yield
- PRCT N/A
- KNSA N/A
- EPS Growth
- PRCT N/A
- KNSA N/A
- EPS
- PRCT N/A
- KNSA 0.07
- Revenue
- PRCT $274,950,000.00
- KNSA $529,332,000.00
- Revenue This Year
- PRCT $47.51
- KNSA $37.21
- Revenue Next Year
- PRCT $31.69
- KNSA $6.10
- P/E Ratio
- PRCT N/A
- KNSA $505.48
- Revenue Growth
- PRCT 55.71
- KNSA 56.18
- 52 Week Low
- PRCT $37.12
- KNSA $17.82
- 52 Week High
- PRCT $103.81
- KNSA $33.98
- Technical
- Relative Strength Index (RSI)
- PRCT 31.84
- KNSA 66.14
- Support Level
- PRCT $37.32
- KNSA $31.78
- Resistance Level
- PRCT $40.86
- KNSA $33.66
- Average True Range (ATR)
- PRCT 2.64
- KNSA 1.26
- MACD
- PRCT -0.67
- KNSA 0.19
- Stochastic Oscillator
- PRCT 24.56
- KNSA 87.34
About PRCT PROCEPT BioRobotics Corporation
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, which are image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.